



Kilitch Drugs (India) Ltd.

11<sup>th</sup> February, 2026

To,  
The Manager – Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai – 400001.

To,  
The Manager – Corporate Compliance  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot No. C-1,  
G Block, BKC, Bandra (E),  
Mumbai – 400051.

**Scrip Code: BSE - 524500**

**Symbol: NSE - KILITCH**

**Sub: Outcome of Board Meeting**

Dear Sir,

Pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, 11<sup>th</sup> February, 2026 have considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31<sup>st</sup> December 2025. The copy of Unaudited Financial Results as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith.
2. Increase in authorized capital from INR 25,00,00,000 to INR 40,00,00,000, subject to members approval.
3. Alteration to the Capital Clause V of the Memorandum of Association of the Company to increase the Authorised Capital from ₹25,00,00,000/- (Rupees Twenty Five crore only) to ₹40,00,00,000/- (Rupees Forty crore only), subject to the approval of the members of the Company.
4. The Board of Directors considered, approved and recommended, subject to members approval at the Extra-ordinary General meeting of the Company, issue of Bonus Shares to members of the Company by capitalization of its reserve in the ratio of 1:1 (1) bonus shares of Rs. 10/- each fully paid for every One (1) existing shares of Rs. 10/- each fully paid up held by the members as on a Record Date to be fixed by the Board thereof for the purpose. The record date for determining the entitlement of the members of the Company to receive bonus equity shares will be announced in due course. Further, the details pertaining to the Bonus issue of equity shares as per Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 as provided in *Annexure – I*
5. Notice of Extra-ordinary General Meeting of the Company to be convened and held on Friday, 13<sup>th</sup> March, 2026 at 11:30 am through video conferencing and other audio visual means only;
6. Appointment of Mr. Deep Shukla & Associates as Practising Company Secretaries as a



Scrutinizer to conduct the entire voting process at the Extra-ordinary General Meeting (including e-voting) and to submit the report for declaration of the results thereof.

7. Appointment of Mr. Dnyaneshwar Kharade, as Internal Auditor of the Company for a period of 5 years with effect from 11<sup>th</sup> February, 2026. Brief Profile is enclosed as Annexure — II

The Board Meeting commenced at 16:30 hours and concluded at 19:30 hours.

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

**Mukund Mehta**  
**Managing Director**  
**DIN: 00147876**



**Annexure I - Details pertaining to the Bonus issue of equity shares as per Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015**

Sr. No.	Particulars	Description
1.	Whether bonus is out of free reserves created out of profits or securities premium account	The Bonus issue of equity shares will be issued out of the Free Reserves and/or Securities Premium Account
2.	Bonus Ratio	1:1 i.e. (1) bonus equity shares of Rs.10/- each fully paid up for every 1(One) equity shares of Rs. 10/- each fully paid up held by members as on the record date to be fixed for the purpose
3.	Details of share capital – Pre and Post bonus issue	Pre-bonus issue paid up share capital: Rs. 17,48,07,820 divided into 1,74,80,782 equity shares of Rs. 10/- each  Post-bonus issue paid up share capital: Rs. 34,96,15,640 divided into 3,49,61,564 equity shares of Rs. 10/- each
4.	Free reserves and / or Securities Premium required for implementing the bonus issue	Rs. 17,48,07,820
5.	Free reserve and / or Securities premium available for capitalization and the date as on such balance is available	As on December 31, 2025 (as per latest unaudited balance sheet)  Free Reserve (including surplus in profit and loss account): Rs. 34,19,81,129.53  Securities Premium: Rs. 94,12,73,748.90
6.	Whether the aforesaid figures are audited	No
7.	Estimated date by which such bonus shares would be credited / dispatched	Within 2 months from the date of approval i.e. by 10 <sup>th</sup> April, 2026



**Annexure – II Brief Profile of Mr. Dnyaneshwar Kharade**

Name	Dnyaneshwar Kharade
Address	Bujavade, Kolhapur Kurani Buzawade Maharashtra – 416509
Email Id	dnyaneshwarkharade@kilitch.com
Area of experience	Accounts, Taxation, Internal Audits, Cost Audits
Disclosure of Relationships between Directors in case of appointment	There is no relationship between directors and the Internal Auditor



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
The Board of Directors of  
**Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter and nine months ended 31st December, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For C. Sharat & Associates  
Chartered Accountants  
Firm No. 128593W



Chintan Sharatchandra Shah  
(Partner)

Membership No. 127551

UDIN: 26127551PTLJNN1404

Date :11/02/2026

Place: Mumbai

**KILITCH DRUGS (INDIA) LIMITED**  
**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025**  
 Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701  
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com  
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

	Three Months Ended			Nine Months Ended		Year Ended	
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>1</b>	<b>Income</b>						
	Net Sales/ Income from operations	4,467.00	3,781.35	4,651.32	11,660.55	12,528.33	18,158.73
	Other Income	160.81	760.89	237.00	1,271.22	1,139.06	1,371.53
	<b>Total Income</b>	<b>4,627.81</b>	<b>4,542.24</b>	<b>4,888.32</b>	<b>12,931.77</b>	<b>13,667.39</b>	<b>19,530.26</b>
<b>2</b>	<b>Expenses</b>						
	Cost of Materials Consumed	2,532.05	1,568.37	2,449.58	5,853.86	6,606.30	9,319.06
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(170.99)	206.90	22.48	(40.18)	28.03	(116.99)
	Employee Benefit Expenses	304.38	328.25	273.02	872.12	744.78	1,003.07
	Finance Cost	60.00	67.86	49.42	186.52	140.46	212.55
	Depreciation and Amortisation Expenses	56.09	52.70	47.49	158.67	122.65	173.72
	Export Product Registration/Commission	538.42	527.11	416.19	1,616.03	1,350.88	1,994.23
	Other Expenses	690.73	783.66	678.23	2,062.06	2,105.16	2,875.63
	<b>Total Expenses</b>	<b>4,010.68</b>	<b>3,534.85</b>	<b>3,936.41</b>	<b>10,709.08</b>	<b>11,098.26</b>	<b>15,461.27</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional Items (1-2)</b>	<b>617.13</b>	<b>1,007.39</b>	<b>951.91</b>	<b>2,222.69</b>	<b>2,569.13</b>	<b>4,068.99</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from ordinary activities before tax (3+4)</b>	<b>617.13</b>	<b>1,007.39</b>	<b>951.91</b>	<b>2,222.69</b>	<b>2,569.13</b>	<b>4,068.99</b>
<b>6</b>	Less: Tax Expenses:-						
	Current Tax	159.79	178.14	286.55	467.79	629.14	985.00
	Deferred Tax	(31.74)	(42.32)	(22.94)	(85.17)	(38.31)	(31.70)
<b>7</b>	<b>Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)</b>	<b>489.08</b>	<b>871.57</b>	<b>688.30</b>	<b>1,840.07</b>	<b>1,978.30</b>	<b>3,115.69</b>
<b>8</b>	Other Comprehensive Income (after tax)	151.04	(229.86)	(123.10)	214.67	(20.28)	(113.68)
<b>9</b>	<b>Total Comprehensive Income (after taxes) (7+8)</b>	<b>640.12</b>	<b>641.71</b>	<b>565.20</b>	<b>2,054.74</b>	<b>1,958.02</b>	<b>3,002.01</b>
<b>10</b>	Paid-Up equity share capital (Face Value Rs 10 per share)	<b>1,748.08</b>	<b>1,748.08</b>	<b>1,608.23</b>	<b>1,748.08</b>	<b>1,608.23</b>	<b>1,608.23</b>
<b>11</b>	Other Equity						<b>23,686.14</b>
<b>12</b>	<b>Earning per share (not annualised)</b>						
	(a) Basic	2.74	5.27	4.28	11.00	12.30	19.37
	(b) Diluted	2.74	5.27	4.28	11.00	12.30	19.37


**Notes:**

- The above Unaudited Standalone Financial Results of the Company for the quarter and nine months ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th February, 2026.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS.
- During the quarter ended 30 September 2025, the Company successfully completed the rights issue of 13,98,463 fully paid up Equity Shares of face value of ₹ 10 each for cash at a price of ₹ 357 per rights equity share (including a premium of ₹ 347 per rights equity share) aggregating up to ₹ 4992.51 lakhs, primarily for funding the capital expenditure for Greenfield Project at Pen. These equity shares were allotted on 25th August 2025.
- The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.
- The Board of Directors of the Company, at their meeting held on 11th February, 2026 have considered, approved and recommended the issuance of 1 bonus equity share on 1 fully paid-up Equity share of face value Rs. 10 each, subject to the approval of the shareholders of the company.

For and on behalf of the Board of Directors

Mukund Mehta  
 Managing Director  
 DIN:- 00147876

Place : Mumbai  
 Dated: 11th February, 2026



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
The Board of Directors of  
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (india) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended 31st December, 2025 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

**List of Subsidiaries:**

1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary



5. (a) We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results reflects, total revenues of Rs. Nil and Rs. Nil for quarter and nine months ended 31st December, 2025 respectively, total Net Profit/(Loss) after tax of Rs. (22.12) Lakhs and Rs. (66.08) Lakhs for quarter and nine months ended 31st December, 2025 respectively, total comprehensive income/(loss) of Rs. (22.12) Lakhs and Rs.(66.08)Lakhs for the quarter and nine months ended 31st December, 2025. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.

(b)The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total revenues of Rs. 925.61 Lakhs and Rs. 2,990.71 Lakhs, total net profit/(loss) after tax of Rs.(35.40) Lakhs and Rs. (312.22) Lakhs and total comprehensive income/(loss) of Rs. (35.40) Lakhs and Rs. (312.22) Lakhs for quarter and nine months ended 31st December, 2025 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management.

Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C. Sharat & Associates  
Chartered Accountants  
Firm No. 128593W



**Chintan Sharatchandra Shah**

(Partner)

Membership No. 127551

UDIN: 26127551HSSFJ07147

Date :11/02/2026

Place: Mumbai

**KILITCH DRUGS (INDIA) LIMITED**  
**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701  
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com  
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED					
		Three Months Ended			Nine Months Ended		Year Ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income</b>						
	Net Sales/Income from Operations	5,380.80	4,892.45	5,616.61	14,587.22	13,709.26	19,831.85
	Other Income	152.81	666.04	172.52	1,074.58	946.31	1,116.06
	<b>Total Income</b>	<b>5,533.61</b>	<b>5,558.49</b>	<b>5,789.13</b>	<b>15,661.80</b>	<b>14,655.57</b>	<b>20,947.91</b>
2	<b>Expenses</b>						
	Cost of Materials Consumed	3,259.75	2,429.28	3,253.57	8,238.03	7,560.24	10,574.97
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(170.99)	206.90	22.48	(40.18)	28.03	(116.99)
	Employee Benefit Expenses	350.84	375.83	314.19	1,001.87	844.31	1,132.38
	Finance Cost	114.69	143.96	140.30	411.64	344.00	504.13
	Depreciation and Amortisation Expenses	93.66	86.28	80.74	264.26	226.35	311.02
	Export Product Registration/Commission	538.61	527.17	416.28	1,616.65	1,351.55	1,995.02
	Other expenses	787.44	849.16	736.49	2,325.15	2,276.36	3,099.96
	<b>Total Expenses</b>	<b>4,974.00</b>	<b>4,618.58</b>	<b>4,964.05</b>	<b>13,817.42</b>	<b>12,630.84</b>	<b>17,500.49</b>
3	<b>Profit before Exceptional items (1-2)</b>	<b>559.61</b>	<b>939.91</b>	<b>825.08</b>	<b>1,844.38</b>	<b>2,024.73</b>	<b>3,447.42</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit from ordinary activities before tax (3+4)</b>	<b>559.61</b>	<b>939.91</b>	<b>825.08</b>	<b>1,844.38</b>	<b>2,024.73</b>	<b>3,447.42</b>
6	Less : Tax Expenses						
	Current Income Tax	159.79	178.14	286.55	467.79	629.14	985.00
	Deferred Tax	(31.72)	(42.23)	(22.94)	(85.16)	(38.25)	(31.59)
7	<b>Profit after tax for the period from continuing operations (5-6)</b>	<b>431.54</b>	<b>804.00</b>	<b>561.47</b>	<b>1,461.75</b>	<b>1,433.84</b>	<b>2,494.01</b>
8	Net Profit/(Loss) After Tax & Share in Profits/(Loss) of Associates	431.54	804.00	561.47	1,461.75	1,433.84	2,494.01
9	Other Comprehensive Income (after Tax)	151.03	(229.86)	(123.10)	214.67	(20.28)	(113.68)
10	<b>Total Comprehensive Income (after taxes) (8+9)</b>	<b>582.57</b>	<b>574.14</b>	<b>438.37</b>	<b>1,676.42</b>	<b>1,413.56</b>	<b>2,380.33</b>
11	<b>Net Profit / (Loss) attributable to</b>						
	a) Owner of the Company	443.22	819.01	596.09	1,564.79	1,591.81	2,670.06
	b) Non Controlling interest	(11.68)	(15.01)	(34.62)	(103.04)	(157.97)	(176.05)
12	<b>Other Comprehensive Income attributable to</b>						
	a) Owner of the Company	151.03	(229.86)	(123.10)	214.67	(20.28)	(113.68)
	b) Non Controlling interest	-	-	-	-	-	-
13	<b>Total Income attributable to</b>						
	a) Owner of the Company	594.25	589.15	472.99	1,779.46	1,571.53	2,556.38
	b) Non Controlling interest	(11.68)	(15.01)	(34.62)	(103.04)	(157.97)	(176.05)
14	<b>Paid-Up equity share capital (Face Value Rs. 10 per share)</b>	<b>1,748.08</b>	<b>1,748.08</b>	<b>1,608.23</b>	<b>1,748.08</b>	<b>1,608.23</b>	<b>1,608.23</b>
15	<b>Other Equity</b>						<b>18,624.68</b>
16	<b>Earning per share (not annualised)</b>						
	(a) Basic	2.50	4.97	3.71	9.35	9.90	16.60
	(b) Diluted	2.50	4.97	3.71	9.35	9.90	16.60

**Notes:**

- The above Unaudited Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 11th February, 2026.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- During the quarter ended 30 September 2025, the Company successfully completed a rights issue of 13,98,463 fully paid up Equity Shares of face value of ₹ 10 each for cash at a price of ₹ 357 per rights equity share (including a premium of ₹ 347 per rights equity share) aggregating up to ₹ 4992.51 lakhs, primarily for funding the capital expenditure for Greenfield Project at Pen. These equity shares were allotted on 25th August 2025.
- The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.
- The Board of Directors of the Company, at their meeting held on 11th February, 2026 have considered, approved and recommended the issuance of 1 bonus equity share on 1 fully paid-up Equity share of face value Rs. 10 each, subject to the approval of the shareholders of the company.

For and on behalf of the Board of Directors

Mukund P. Mehta  
 Managing Director  
 DIN : 00147876

Place: Mumbai  
 Date: 11th February, 2026

